1887

Abstract

Prion diseases are presumed to be caused by the accumulation in the brain of a pathological protein called prion protein (PrP) scrapie which results from the transconformation of cellular PrP, a ubiquitous glycoprotein expressed in all mammals. Since all isoforms of PrP are perceived as self by the host immune system, a major problem in designing efficient immunoprophylaxis or immunotherapy is to overcome tolerance. The present study was aimed at investigating whether bone-marrow-derived dendritic cells (DCs) loaded with peptides previously shown to be immunogenic in PrP-deficient mice, can overcome tolerance in PrP-proficient wild-type mice and protect them against scrapie. Results show that, in such mice, peptide-loaded DCs elicit both lymphokine release by T cells and antibody secretion against native cellular PrP. Repeated recalls with peptide-loaded DCs reduces the attack rate of 139A scrapie inoculated intraperitoneally and retards disease duration by 40 days. Most interestingly, survival time in individual mice appears to be correlated with the level of circulating antibody against native cellular PrP.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.013417-0
2010-03-01
2019-11-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/91/3/809.html?itemId=/content/journal/jgv/10.1099/vir.0.013417-0&mimeType=html&fmt=ahah

References

  1. Aucouturier, P., Geissmann, F., Damotte, D., Saborio, G. P., Meeker, H. C., Kascsak, R., Carp, R. I. & Wisniewski, T. ( 2001; ). Infected splenic dendritic cells are sufficient for prion transmission to the CNS in mouse scrapie. J Clin Invest 108, 703–708.[CrossRef]
    [Google Scholar]
  2. Bade, S., Baier, M., Boetel, T. & Frey, A. ( 2006; ). Intranasal immunization of Balb/c mice against prion protein attenuates orally acquired transmissible spongiform encephalopathy. Vaccine 24, 1242–1253.[CrossRef]
    [Google Scholar]
  3. Ballerini, C., Gourdain, P., Bachy, V., Blanchard, N., Levavasseur, E., Gregoire, S., Fontes, P., Aucouturier, P., Hivroz, C. & Carnaud, C. ( 2006; ). Functional implication of cellular prion protein in antigen-driven interactions between T cells and dendritic cells. J Immunol 176, 7254–7262.[CrossRef]
    [Google Scholar]
  4. Bergtold, A., Desai, D. D., Gavhane, A. & Clynes, R. ( 2005; ). Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity 23, 503–514.[CrossRef]
    [Google Scholar]
  5. Boscardin, S. B., Hafalla, J. C., Masilamani, R. F., Kamphorst, A. O., Zebroski, H. A., Rai, U., Morrot, A., Zavala, F., Steinman, R. M. & other authors ( 2006; ). Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med 203, 599–606.[CrossRef]
    [Google Scholar]
  6. Brown, K. L., Stewart, K., Ritchie, D. L., Mabbott, N. A., Williams, A., Fraser, H., Morrison, W. I. & Bruce, M. E. ( 1999; ). Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells. Nat Med 5, 1308–1312.[CrossRef]
    [Google Scholar]
  7. Bueler, H., Fischer, M., Lang, Y., Bluethmann, H., Lipp, H. P., DeArmond, S. J., Prusiner, S. B., Aguet, M. & Weissmann, C. ( 1992; ). Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356, 577–582.[CrossRef]
    [Google Scholar]
  8. Charalambous, A., Oks, M., Nchinda, G., Yamazaki, S. & Steinman, R. M. ( 2006; ). Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin. J Immunol 177, 8410–8421.[CrossRef]
    [Google Scholar]
  9. Cormont, F., Manouvriez, P., De Clercq, L. & Bazin, H. ( 1986; ). The use of rat monoclonal antibodies to characterize, quantify, and purify polyclonal or monoclonal mouse IgM. Methods Enzymol 121, 622–631.
    [Google Scholar]
  10. Donne, D. G., Viles, J. H., Groth, D., Mehlhorn, I., James, T. L., Cohen, F. E., Prusiner, S. B., Wright, P. E. & Dyson, H. J. ( 1997; ). Structure of the recombinant full-length hamster prion protein PrP(29–231): the N terminus is highly flexible. Proc Natl Acad Sci U S A 94, 13452–13457.[CrossRef]
    [Google Scholar]
  11. Fay, J. W., Palucka, A. K., Paczesny, S., Dhodapkar, M., Johnston, D. A., Burkeholder, S., Ueno, H. & Banchereau, J. ( 2006; ). Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother 55, 1209–1218.[CrossRef]
    [Google Scholar]
  12. Fernandez-Borges, N., Brun, A., Whitton, J. L., Parra, B., Diaz-San Segundo, F., Salguero, F. J., Torres, J. M. & Rodriguez, F. ( 2006; ). DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge. J Virol 80, 9970–9976.[CrossRef]
    [Google Scholar]
  13. Glatzel, M. & Aguzzi, A. ( 2000; ). PrP(C) expression in the peripheral nervous system is a determinant of prion neuroinvasion. J Gen Virol 81, 2813–2821.
    [Google Scholar]
  14. Goni, F., Prelli, F., Schreiber, F., Scholtzova, H., Chung, E., Kascsak, R., Brown, D. R., Sigurdsson, E. M., Chabalgoity, J. A. & Wisniewski, T. ( 2008; ). High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice. Neuroscience 153, 679–686.[CrossRef]
    [Google Scholar]
  15. Gregoire, S., Logre, C., Metharom, P., Loing, E., Chomilier, J., Rosset, M. B., Aucouturier, P. & Carnaud, C. ( 2004; ). Identification of two immunogenic domains of the prion protein – PrP – which activate class II-restricted T cells and elicit antibody responses against the native molecule. J Leukoc Biol 76, 125–134.[CrossRef]
    [Google Scholar]
  16. Gregoire, S., Bergot, A. S., Feraudet, C., Carnaud, C., Aucouturier, P. & Rosset, M. B. ( 2005; ). The murine B cell repertoire is severely selected against endogenous cellular prion protein. J Immunol 175, 6443–6449.[CrossRef]
    [Google Scholar]
  17. Gruber, A., Chalmers, A. S., Rasmussen, R. A., Ong, H., Popov, S., Andersen, J., Hu, S. L. & Ruprecht, R. M. ( 2007; ). Dendritic cell-based vaccine strategy against human immunodeficiency virus clade C: skewing the immune response toward a helper T cell type 2 profile. Viral Immunol 20, 160–169.[CrossRef]
    [Google Scholar]
  18. Heikenwalder, M., Polymenidou, M., Junt, T., Sigurdson, C., Wagner, H., Akira, S., Zinkernagel, R. & Aguzzi, A. ( 2004; ). Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 10, 187–192.[CrossRef]
    [Google Scholar]
  19. Heppner, F. L., Musahl, C., Arrighi, I., Klein, M. A., Rulicke, T., Oesch, B., Zinkernagel, R. M., Kalinke, U. & Aguzzi, A. ( 2001; ). Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294, 178–182.[CrossRef]
    [Google Scholar]
  20. Herrera, O. B., Golshayan, D., Tibbott, R., Salcido Ochoa, F., James, M. J., Marelli-Berg, F. M. & Lechler, R. I. ( 2004; ). A novel pathway of alloantigen presentation by dendritic cells. J Immunol 173, 4828–4837.[CrossRef]
    [Google Scholar]
  21. Levavasseur, E., Metharom, P., Dorban, G., Nakano, H., Kakiuchi, T., Carnaud, C., Sarradin, P. & Aucouturier, P. ( 2007; ). Experimental scrapie in ‘plt’ mice: an assessment of the role of dendritic-cell migration in the pathogenesis of prion diseases. J Gen Virol 88, 2353–2360.[CrossRef]
    [Google Scholar]
  22. Lu, W., Wu, X., Lu, Y., Guo, W. & Andrieu, J. M. ( 2003; ). Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 9, 27–32.
    [Google Scholar]
  23. Mabbott, N. A., Mackay, F., Minns, F. & Bruce, M. E. ( 2000; ). Temporary inactivation of follicular dendritic cells delays neuroinvasion of scrapie. Nat Med 6, 719–720.[CrossRef]
    [Google Scholar]
  24. Matzinger, P. ( 1998; ). An innate sense of danger. Semin Immunol 10, 399–415.[CrossRef]
    [Google Scholar]
  25. Montrasio, F., Frigg, R., Glatzel, M., Klein, M. A., Mackay, F., Aguzzi, A. & Weissmann, C. ( 2000; ). Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science 288, 1257–1259.[CrossRef]
    [Google Scholar]
  26. Nair, S. K., Heiser, A., Boczkowski, D., Majumdar, A., Naoe, M., Lebkowski, J. S., Vieweg, J. & Gilboa, E. ( 2000; ). Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 6, 1011–1017.[CrossRef]
    [Google Scholar]
  27. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G. & Schadendorf, D. ( 1998; ). Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4, 328–332.[CrossRef]
    [Google Scholar]
  28. Nikles, D., Bach, P., Boller, K., Merten, C. A., Montrasio, F., Heppner, F. L., Aguzzi, A., Cichutek, K., Kalinke, U. & Buchholz, C. J. ( 2005; ). Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP. J Virol 79, 4033–4042.[CrossRef]
    [Google Scholar]
  29. Palucka, A. K., Connolly, J., Ueno, H., Kohl, J., Paczesny, S., Dhodapkar, M., Fay, J. & Banchereau, J. ( 2005; ). Spontaneous proliferation and type 2 cytokine secretion by CD4+ T cells in patients with metastatic melanoma vaccinated with antigen-pulsed dendritic cells. J Clin Immunol 25, 288–295.[CrossRef]
    [Google Scholar]
  30. Palucka, A. K., Ueno, H., Connolly, J., Kerneis-Norvell, F., Blanck, J. P., Johnston, D. A., Fay, J. & Banchereau, J. ( 2006; ). Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 29, 545–557.[CrossRef]
    [Google Scholar]
  31. Polymenidou, M., Heppner, F. L., Pellicioli, E. C., Urich, E., Miele, G., Braun, N., Wopfner, F., Schatzl, H. M., Becher, B. & Aguzzi, A. ( 2004; ). Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc Natl Acad Sci U S A 101, (Suppl. 2), 14670–14676.[CrossRef]
    [Google Scholar]
  32. Prusiner, S. B., Scott, M. R., DeArmond, S. J. & Cohen, F. E. ( 1998; ). Prion protein biology. Cell 93, 337–348.[CrossRef]
    [Google Scholar]
  33. Qi, H., Egen, J. G., Huang, A. Y. & Germain, R. N. ( 2006; ). Extrafollicular activation of lymph node B cells by antigen-bearing dendritic cells. Science 312, 1672–1676.[CrossRef]
    [Google Scholar]
  34. Rosset, M. B., Ballerini, C., Gregoire, S., Metharom, P., Carnaud, C. & Aucouturier, P. ( 2004; ). Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice. J Immunol 172, 5168–5174.[CrossRef]
    [Google Scholar]
  35. Rosset, M. B., Sacquin, A., Lecollinet, S., Chaigneau, T., Adam, M., Crespeau, F. & Eloit, M. ( 2009; ). Dendritic cell-mediated-immunization with xenogenic PrP and adenoviral vectors breaks tolerance and prolongs mice survival against experimental scrapie. PLoS One 4, e4917 [CrossRef]
    [Google Scholar]
  36. Sacquin, A., Bergot, A. S., Aucouturier, P. & Bruley-Rosset, M. ( 2008; ). Contribution of antibody and T cell-specific responses to the progression of 139A-scrapie in C57BL/6 mice immunized with prion protein peptides. J Immunol 181, 768–775.[CrossRef]
    [Google Scholar]
  37. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K. & other authors ( 1999; ). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177.[CrossRef]
    [Google Scholar]
  38. Schwarz, A., Kratke, O., Burwinkel, M., Riemer, C., Schultz, J., Henklein, P., Bamme, T. & Baier, M. ( 2003; ). Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci Lett 350, 187–189.[CrossRef]
    [Google Scholar]
  39. Sigurdsson, E. M., Brown, D. R., Daniels, M., Kascsak, R. J., Kascsak, R., Carp, R., Meeker, H. C., Frangione, B. & Wisniewski, T. ( 2002; ). Immunization delays the onset of prion disease in mice. Am J Pathol 161, 13–17.[CrossRef]
    [Google Scholar]
  40. Sigurdsson, E. M., Sy, M. S., Li, R., Scholtzova, H., Kascsak, R. J., Kascsak, R., Carp, R., Meeker, H. C., Frangione, B. & Wisniewski, T. ( 2003; ). Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci Lett 336, 185–187.[CrossRef]
    [Google Scholar]
  41. Weigel, B. J., Nath, N., Taylor, P. A., Panoskaltsis-Mortari, A., Chen, W., Krieg, A. M., Brasel, K. & Blazar, B. R. ( 2002; ). Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of anti-leukemia responses. Blood 100, 4169–4176.[CrossRef]
    [Google Scholar]
  42. White, A. R., Enever, P., Tayebi, M., Mushens, R., Linehan, J., Brandner, S., Anstee, D., Collinge, J. & Hawke, S. ( 2003; ). Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422, 80–83.[CrossRef]
    [Google Scholar]
  43. Wierecky, J., Müller, M. R., Wirths, S., Halder-Oehler, E., Dörfel, D., Schmidt, S. M., Häntschel, M., Brugger, W., Schröder, S. & other authors ( 2006; ). Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66, 5910–5918.[CrossRef]
    [Google Scholar]
  44. Wisniewski, T., Aucouturier, P., Soto, C. & Frangione, B. ( 1998; ). The prionoses and other conformational disorders. Amyloid 5, 212–224.[CrossRef]
    [Google Scholar]
  45. Wykes, M., Pombo, A., Jenkins, C. & MacPherson, G. G. ( 1998; ). Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J Immunol 161, 1313–1319.
    [Google Scholar]
  46. Yu, J. S., Liu, G., Ying, H., Yong, W. H., Black, K. L. & Wheeler, C. J. ( 2004; ). Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64, 4973–4979.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.013417-0
Loading
/content/journal/jgv/10.1099/vir.0.013417-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error